Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
BMC Cancer. 2023 Mar 28;23(1):281. doi: 10.1186/s12885-023-10764-y.
Residual fibroglandular breast tissue (RFGT) following a mastectomy has been claimed to be associated with the occurrence of an in-breast local recurrence (IBLR) or new primary tumor (NP). Yet, scientific evidence proving this assumption is lacking. The primary aim of the study was to verify whether RFGT following a mastectomy is a risk factor for an IBLR or NP.
This retrospective analysis included all patients that underwent a mastectomy and were followed up at the Department of Obstetrics and Gynecology of the Medical University of Vienna between 01.01.2015 and 26.02.2020. RFGT volume (assessed on magnetic resonance imaging) was correlated with the prevalence of an IBLR and a NP.
A total of 105 patients (126 breasts) following a therapeutic mastectomy were included. After a mean follow-up of 46.0 months an IBLR had occurred in 17 breasts and a NP in 1 breast. A significant difference in RFGT volume was observed between the disease-free cohort and the subgroup with an IBLR or NP (p = .017). A RFGT volume of ≥ 1153 mm increased the risk by the factor 3.57 [95%CI 1.27; 10.03].
RFGT volume is associated with an increased risk for an IBLR or NP.
据报道，乳房切除术后残留的纤维腺体组织（RFGT）与乳房内局部复发（IBLR）或新原发性肿瘤（NP）的发生有关。然而，缺乏证明这一假设的科学证据。该研究的主要目的是验证乳房切除术后的 RFGT 是否是 IBLR 或 NP 的危险因素。
本回顾性分析纳入了 2015 年 1 月 1 日至 2020 年 2 月 26 日期间在维也纳医科大学妇产科接受乳房切除术并接受随访的所有患者。通过磁共振成像评估 RFGT 体积，并将其与 IBLR 和 NP 的发生率相关联。
共纳入 105 例（126 侧乳房）接受保乳治疗的患者。平均随访 46.0 个月后，17 侧乳房出现 IBLR，1 侧乳房出现 NP。在无疾病组和 IBLR 或 NP 亚组之间，RFGT 体积存在显著差异（p = .017）。RFGT 体积≥1153mm 时，风险增加 3.57 倍（95%CI 1.27；10.03）。
RFGT 体积与 IBLR 或 NP 的风险增加相关。
